{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-COV-2+mRNA+Vaccine",
    "query": {
      "intervention": "SARS-COV-2 mRNA Vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 135,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-COV-2+mRNA+Vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T02:26:48.702Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06633835",
      "title": "Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19",
        "Vaccine-Preventable Diseases",
        "SARS CoV 2 Infection"
      ],
      "interventions": [
        {
          "name": "protein subunit: Novavax COVID-19 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pfizer mRNA COVID-19 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2024-09-19",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06633835"
    },
    {
      "nct_id": "NCT05975060",
      "title": "A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "XBB.1.5 Vaccine (Booster)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "XBB.1.5 Vaccine (single dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "18 Years to 54 Years"
      },
      "enrollment_count": 660,
      "start_date": "2023-09-07",
      "completion_date": "2024-05-20",
      "has_results": false,
      "last_update_posted_date": "2024-05-30",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05975060"
    },
    {
      "nct_id": "NCT05260437",
      "title": "Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CV2CoV (2 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (4 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (8 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (12 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (16 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (20 µg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2022-03-24",
      "completion_date": "2023-03-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 24,
      "location_summary": "Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05260437"
    },
    {
      "nct_id": "NCT04887948",
      "title": "Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Disease",
        "COVID-19",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "20-valent pneumococcal conjugate vaccine (20vPnC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 570,
      "start_date": "2021-05-20",
      "completion_date": "2021-12-08",
      "has_results": true,
      "last_update_posted_date": "2022-12-14",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 27,
      "location_summary": "Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04887948"
    },
    {
      "nct_id": "NCT05054218",
      "title": "COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19",
        "SARS-CoV2 Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 336,
      "start_date": "2021-09-10",
      "completion_date": "2022-08-29",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05054218"
    },
    {
      "nct_id": "NCT04847050",
      "title": "A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor Malignancy",
        "Hematologic Malignancy",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ECG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Antibiotics",
          "type": "OTHER"
        },
        {
          "name": "Anti-viral agents",
          "type": "OTHER"
        },
        {
          "name": "Anti-fungal agent",
          "type": "OTHER"
        },
        {
          "name": "Anti-emetics",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2021-04-28",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04847050"
    },
    {
      "nct_id": "NCT05004181",
      "title": "Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19",
        "SARS-CoV-2 Acute Respiratory Disease",
        "SARS (Disease)"
      ],
      "interventions": [
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent BNT162b2 (B.1.1.7)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent BNT162b2 (B.1.617.2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent BNT162b2 (B.1.1.529.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1380,
      "start_date": "2021-08-25",
      "completion_date": "2023-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 14,
      "location_summary": "Long Beach, California • San Diego, California • Milford, Connecticut + 10 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004181"
    },
    {
      "nct_id": "NCT05019456",
      "title": "Exercise and COVID-19 Viral T-cell Immunity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19 Respiratory Infection",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "44 Years",
        "sex": "ALL",
        "summary": "18 Years to 44 Years"
      },
      "enrollment_count": 26,
      "start_date": "2021-03-09",
      "completion_date": "2025-12-25",
      "has_results": false,
      "last_update_posted_date": "2025-03-27",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05019456"
    },
    {
      "nct_id": "NCT06130345",
      "title": "Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "SPIKEVAX",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15196685,
      "start_date": "2023-04-14",
      "completion_date": "2024-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06130345"
    },
    {
      "nct_id": "NCT04847596",
      "title": "A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "OTHER"
        },
        {
          "name": "Covid-19 vaccine",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-05-21",
      "completion_date": "2022-02-18",
      "has_results": false,
      "last_update_posted_date": "2023-01-25",
      "last_synced_at": "2026-09-28T02:26:48.702Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Owosso, Michigan • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Owosso",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Plainview",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04847596"
    }
  ]
}